跳至主要内容
临床试验/TCTR20211102003
TCTR20211102003已完成3 期

An Immunogenicity study of An Additional Dose of COVID-19 Vaccine in Kidney Transplant Recipients

ational Research Council of Thailand0 个研究点目标入组 120 人开始时间: 2021年11月2日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • All adult kidney transplant recipients who were fully vaccinated with SARS-CoV-2 vaccine however with inadequate immune response

排除标准

  • Declined to participate
  • Allergic to vaccine given

研究者

发起方
ational Research Council of Thailand

相似试验

招募中
4 期
OCV_Delayed ProtocolCholera
PACTR202206663504683MSF OCB456
已完成
不适用
Immunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis ~ Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component.Infectious Diseases, Whooping Cough, Pertussis, Infectieziekten, Kinkhoest
NL-OMON22816ational Institute for Public Health and the Environment (RIVM)400
已完成
不适用
Immunogenicity and adjuvant effect of the whole cell Pertussis component of the Dutch combined Diphtheria, Tetanus, Pertussis, Poliomyelitis - Haemophilus influenzae type b vaccine in infants compared to the old whole cell P vaccine and a new acellular P vaccine component
ISRCTN97785537ational Institute of Public Health and Environmental Protection (RIVM) (The Netherlands)400
进行中(未招募)
1 期
Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated poliomyelitis vaccine (DT Polio®) when given as a booster dose at 6 years of age - REVAXIS® versus DT Polio® as a second booster in 6 year-old childreot applicable - Healthy volunteers - 6 year-old child
EUCTR2005-001446-16-FRSanofi Pasteur MSD760
已完成
不适用
A study to determine the effect of post-infusion cooling time in the high dose 5-fluorouracil, 4-epidoxorubicin and cyclophosphamide (FEC)-regimeBreast cancer, hair lossCancer
ISRCTN97879847Medical Centre Alkmaar (Medisch Centrum Alkmaar) (The Netherlands)130